Visual Atlas · Science (frontier)
Psychoplastogens
Can you keep the brain rewiring and drop the trip? Olson's hypothesis is that the hallucination and the healing may be separable — a frontier idea with real animal signal and the earliest-stage human data.
90-second quick read · deeper research available
Need the deeper research library?
This is the 90-second cliff-note read on imicrodosing.net. For cited research context, terminology, and broader education, use the full .org research library.
In brief
A psychoplastogen is a compound that rapidly promotes structural neuroplasticity, the way psychedelics do. The frontier question, advanced by David Olson at UC Davis, is whether that plasticity can be produced without the hallucinogenic experience — by engineering analogues such as tabernanthalog that keep the growth-promoting mechanism but reduce or remove the trip.
The animal evidence is real: non-hallucinogenic analogues have produced plasticity and antidepressant-like effects in rodents, and companies such as Delix Therapeutics are developing candidates. Whether the trip is dispensable for human therapeutic benefit is genuinely contested. Promising, unproven — animal data shows real signal; human data is earliest-stage.
Visual walkthrough
Swipe or tap the arrows to move through 10 slides
The separability hypothesis and where it stands
The definition
A psychoplastogen is a fast-acting promoter of structural neuroplasticity. Classic psychedelics qualify; the frontier work is on analogues that keep the plasticity and reduce the trip.
The separability hypothesis
Olson's hypothesis is that the hallucinogenic experience and the plasticity-promoting mechanism may be separable. This is explicitly a hypothesis, not a settled claim.
Tabernanthalog
Tabernanthalog is an ibogaine-inspired analogue engineered to retain plasticity-promoting activity while reducing hallucinogenic and cardiotoxic properties in animal models.
Shared pathways
The analogues engage the same TrkB and mTOR growth pathways that psychedelics activate — the mechanism is shared even where the subjective effect is not.
The counter-argument
Many clinicians hold that the subjective experience is itself therapeutic. If so, a non-tripping compound would lose part of the benefit. The debate is unresolved.
The pipeline
Delix Therapeutics and others are developing non-hallucinogenic candidates. As of 2026, human therapeutic confirmation is the earliest-stage evidence covered here.
What the data shows — and how strong it is
Verdict
Promising, but unproven. Animal findings justify research; they do not establish human therapeutic effectiveness.
Common questions
Answered directly
Q · 01
What is a psychoplastogen?
A psychoplastogen is a compound that rapidly promotes structural neuroplasticity, the way classic psychedelics do. The term is used especially for engineered analogues, such as tabernanthalog, designed to keep the plasticity-promoting mechanism while reducing or removing the hallucinogenic experience.
Q · 02
Can you get the benefits of psychedelics without the trip?
This is the central open question. Olson's hypothesis is that plasticity and hallucination may be separable, and non-hallucinogenic analogues have produced plasticity and antidepressant-like effects in animals. Whether this translates to human therapeutic benefit is the earliest-stage evidence in this area and is genuinely contested.
Q · 03
What is tabernanthalog?
Tabernanthalog is an ibogaine-inspired analogue developed in David Olson's UC Davis lab, engineered to retain plasticity-promoting activity while reducing the hallucinogenic and cardiotoxic effects of ibogaine in animal models. It is a lead example of the psychoplastogen approach.
Product-format context
For product-format context, see the iMicrodosing.com products and client support.
View products & support →